Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sunshine Biopharma Inc. - Warrant
(NQ:
SBFMW
)
0.1400
+0.0480 (+52.17%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sunshine Biopharma Inc. - Warrant
Sunshine Biopharma Q2 Report Reveals Approximately 1,940% Increase In Cash & Cash Equivalents And 80% Decrease In Net Loss Within 6 Months
August 08, 2022
Sunshine Biopharma, Inc. (NASDAQ: SBFM) (NASDAQ: SBFMW) announced that it has filed its 2022 second-quarter report with the Securities and Exchange Commission.
Via
Benzinga
Sunshine Biopharma Reveals Potential Intellectual Property Position In Connection With Ongoing mRNA-As-Therapeutics-Agents Research
April 26, 2022
Photo credit: Patent application by Nick Youngson CC BY-SA 3.0
Via
Benzinga
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
April 25, 2022
Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc.
Via
Benzinga
Sunshine Biopharma Sees Potential Multi-Billion Dollar Global Market Opportunity As Research Findings Reveal Effectiveness Against Multidrug-Resistant Cancer Cells
April 06, 2022
Photo by Angiola Harry on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Sunshine Biopharma, Inc. Announces Pricing of $8 Million Private Placement Priced At-the-Market
March 14, 2022
Photo by Scott Graham on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW)
February 17, 2022
NEW YORK, NY / ACCESSWIRE / February 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ:SBFM; SBFMW)...
From
Aegis Capital Corp.
Via
AccessWire
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.